DeSena Allen D, Noland Daniel K, Matevosyan Karen, King Kathryn, Phillips Lauren, Qureshi Sara S, Greenberg Benjamin M, Graves Donna
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.
Department of Neurology, Children's Medical Center, Dallas, Texas.
J Clin Apher. 2015 Aug;30(4):212-6. doi: 10.1002/jca.21363. Epub 2015 Feb 9.
Anti-N-methyl-d-aspartate (NMDA) receptor antibody encephalitis is an increasingly recognized form of autoimmune encephalitis. Conventional treatments include therapies such as corticosteroids, intravenous immunoglobulin (IVIg), and/or therapeutic plasma exchange (TPE). Although TPE is regularly used for treatment of anti-NMDA receptor antibody encephalitis, the American Society for Apheresis has given it a category III recommendation only. Earlier administered immunotherapies in tumor-negative patients may facilitate faster recoveries, but it remains unclear whether or not TPE is superior to steroids and/or IVIG.
We retrospectively evaluated 10 of 14 patients that received steroids and TPE with modified Rankin scores and subjectively assessed the point of largest sustained improvement in all 14 patients.
In the patients that received both steroids and TPE at our institution during the same hospitalization (only 10 of 14 patients), 7/10 patients after TPE had improved with the modified Rankin score versus 3/10 patients after steroids. The average modified Rankin score improvement after steroids in this group was -0.1 as compared with 0.4 after TPE. Based on subjective chart review analysis during which all 14 patients were assessed, the largest sustained improvement occurred immediately following the third-fifth exchange in 9/14 patients, whereas only 2/14 patients appeared to have had significant benefit immediately following steroids.
This is compelling preliminary data that suggests that corticosteroids may not be as effective compared to steroids followed by TPE. Given the importance of time-sensitive treatment, more formal studies may illuminate the ideal first-line treatment for anti-NMDA receptor antibody encephalitis.
抗N-甲基-D-天冬氨酸(NMDA)受体抗体脑炎是一种日益被认识的自身免疫性脑炎形式。传统治疗方法包括使用皮质类固醇、静脉注射免疫球蛋白(IVIg)和/或治疗性血浆置换(TPE)等疗法。虽然TPE经常用于治疗抗NMDA受体抗体脑炎,但美国单采学会仅将其列为III类推荐。在肿瘤阴性患者中更早给予免疫治疗可能有助于更快康复,但TPE是否优于类固醇和/或IVIG仍不清楚。
我们回顾性评估了14例接受类固醇和TPE治疗患者中的10例,采用改良Rankin量表评分,并主观评估了所有14例患者最大持续改善点。
在我们机构同一住院期间同时接受类固醇和TPE治疗的患者(14例中仅10例)中,TPE后10例患者中有7例改良Rankin量表评分有所改善,而类固醇治疗后10例患者中有3例改善。该组患者类固醇治疗后改良Rankin量表评分平均改善-0.1,而TPE后为0.4。基于对所有14例患者进行评估的主观病历审查分析,14例患者中有9例在第三次至第五次置换后立即出现最大持续改善,而只有2例患者在接受类固醇治疗后立即显示出显著获益。
这是令人信服的初步数据,表明与先使用类固醇再进行TPE相比,单纯使用皮质类固醇可能效果不佳。鉴于时间敏感型治疗的重要性,更正式的研究可能会阐明抗NMDA受体抗体脑炎的理想一线治疗方法。